

**\$400 EARLY
BOOKING SAVINGS**

17-18 September, 2019 | Singapore
www.microbiome-movement-asia.com

MICROBIOME MOVEMENT **DRUG DEVELOPMENT & NUTRITION** *Asia*

**Join the Premier Event for the Microbiome
Community within APAC to Advance the Future
Generation of Safe, Effective and Commercially
Viable Microbiome-Based Therapeutics &
Nutritional Products**



Yang Bo Gie
Chief Scientific Officer
GI Innovation



GwangPyo Ko
Professor
Seoul National University
CEO
KoBioLabs



Yiming Yin
VP, Research & Product
Development
XBiome



Jae-Gu Pan
CTO
GenoFocus



Jisoo Pae
Founder & CEO
Genome and Company



Jon Sik Chun
Professor
Seoul National University



Takuji Yamada
Associate Professor
Tokyo Institute of Technology



Yoshiyuki Sakuraba
CEO
Varinos

Proudly Sponsored By:



www.microbiome-movement-asia.com

US Tel: +1 617 455 4188 Email: info@microbiome-movement.com  **@MicrobiomeDaily**



THE MICROBIOME MOVEMENT UNITES ACADEMIC AND INDUSTRY LEADERS TO HELP ADVANCE HUMAN MICROBIOME RESEARCH WITHIN APAC, IDENTIFY NOVEL PRODUCT OPPORTUNITIES, AND DELIVER A NEW FUTURE FOR HEALTHCARE

A LETTER FROM OUR PROGRAM DIRECTOR & CO-FOUNDER

Dear Microbiome Enthusiasts,

Scientific and commercial research linking the microbiome to improve human health and disease is on a rapid growth trajectory. Driven by a decreasing costs in sequencing, mechanistic breakthroughs and advancing clinical developments, **products that target the human microbiome are set to completely transform the healthcare industry.**

Recent scientific advances have led to the emergence of a completely new industry dedicated to translating and exploiting a complex science towards commercial reality, spanning across pharmaceutical, nutritional and cosmetic sectors.

Part of the globally recognised *Microbiome Movement*, we are delighted to announce the arrival of the inaugural **Microbiome Movement – Drug Development & Nutrition Summit** taking place in Singapore this September, to help translational microbiome researchers in APAC discover, develop and deliver the future generation of microbiome-based products across therapeutic and nutritional industry applications.

This year's forum will play an important role in reviewing the major scientific and commercial progress areas in microbiome research within APAC, and will also help you build new business opportunities in this new and exciting field. Interact with industry and academic key opinion leaders from the prominent microbiome researchers and organisations to accelerate your knowledge of the field, overcome key challenges in translating your microbiome research to commercial reality, and help bring a future generation of microbiome-based products to the marketplace.

It is with great pleasure and enthusiasm that I invite you to join the *Microbiome Movement* and I look forward to meeting many of you in Singapore.

Sincerely,



Alexander Puttick

Program Director & Co-Founder
Microbiome Movement

3 KEY TOPICS

Science

Mechanisms, Sequencing & Bioinformatics

- Host-Microbiome Interactions that Cause Disease
- Establishing Standardised Protocols
- Sequencing, Bioinformatics & Big Data

Applications

Therapeutics, Nutrition & Diagnostics

- Live-Biotherapeutic Discovery & Development
- Metabolite-Based Microbiome Products
- Microbiome-Based Biomarkers and Diagnostics
- Role of the Human Microbiome in Diet & Nutrition

Policy

Regulation & Investment

- Collaborations & Consortia to Support Microbiome efforts
- Regulatory Frameworks for Microbiome-Based Products
- Microbiome Investment Landscape within the Asia-Pacific Region

JOIN THE MICROBIOME MOVEMENT



January 2020: Paris, FR
www.microbiome-europe.com

"It was a great conference to effectively learn the current trends in microbiome drug development around the world"

Nanae Izumi, Senior Researcher, Daiichi Sankyo



February 2020: Raleigh, NC
www.microbiome-agbiotech.com

"Possibly the best conference in the agricultural microbiome space - a great mix of basic scientific research and product development from universities, multinationals and start-up companies. Congratulations!"

Marcus Meadows-Smith, CEO, BioConsortia



May 2019: Boston, MA
www.microbiome-infant-health.com

"This is great opportunity to learn and connect with thought leaders who are on the forefront in the emerging areas of maternal and infant microbiome health"

Noah Voreades, GenBiome Consulting, Confirmed Speaker



June 2019: Boston, MA
www.microbiome-summit.com

"This meeting is possibly the best in the microbiome field for a biotech company, for networking and hearing the latest developments"

Mike Romanos, CEO, Microbiotica



July 2019: Boston, MA
www.microbiome-oncology.com

"This is a timely event in light of recent research published on the microbiome and cancer immunotherapy. I look forward to a productive discussion forum"

Xue Liang, Senior Scientist, Microbiome/Molecular Scientist, Merck Exploratory Science Center



September 2019: San Diego, CA
www.microbiome-dermatology.com

"This meeting was the perfect balance between basic/applied science and academic/commercial interest"

Greg Hillebrand, Senior Principal Research Scientist, Amway



November 2019: Boston, MA
www.microbiome-nutrition.com

"If you want to learn about the latest developments and mix with the movers and shakers in the industry, you HAVE to be there"

Alan Murray, CEO, NextFoods Inc



December 2019: Boston, MA
www.gutbrain-axis.com

"It is one of the best meeting I've been to! Great job!"

Yanjiao Zhou, Research Scientist, The Jackson Laboratory

WORLD-CLASS SPEAKER FACULTY



Jonathan Krive
CEO
AsiaBiome



Ken Kasahara
General Manager of Microbiome Area
Chitose Bio



Christophe Lay
Senior Scientist, Gut Microbiome
Danone Nutricia Research



Jae-Gu Pan
CTO
GenoFocus



Jisoo Pae
Founder & CEO
Genome and Company



Yang Bo Gie
Chief Scientific Officer
GI Innovation



Suenie Park
Professor
Hallym University



Ki-Tae Suk
Associate Professor
Hallym University Medical Center



Changsoo Eun
Professor, Internal Medicine
Hanyang University College of Medicine



GwangPyo Ko
Professor
Seoul National University
CEO KoBioLabs



Taewook Nam
CTO
KoBioLabs



Heenam Stanley Kim
Professor
Korea University, College of Health Sciences



Wang-Jun Lee MD
CEO & Chairman
MyongJi Hospital



Lee Yuan Kun
Associate Professor
National University of Singapore



Yasunori Yonejima
Group Manager
Nitto Pharmaceuticals



Hiroshi Ohno MD
Principal Investigator
RIKEN Center for Integrative Medical Sciences



Jon Sik Chun
Professor
Seoul National University



Shingo Arioka
Research Manager
Shionogi & Japan
Microbiome Consortium



Yoshiyuki Sakuraba
CEO
Varinos



Takuji Yamada
Associate Professor
Tokyo Institute of Technology



Yiming Yin
VP, Research & Product Development
XBiome

SCIENCE, MECHANISMS & SEQUENCING

7.50 **Registration & Morning Coffee**



8.50 **Chairperson Opening Remarks**



Shingo Arioka
Research Manager
Shionogi & Japan Microbiome Consortium

Host-Microbiome Interactions that Cause Disease

Session Purpose:

As the gut microbiome continues to be at the forefront of medical research, both the industrial and academic communities expect that insights gained from microorganisms will soon become a critical component of health management across a gamut of critical indications. However, the biggest hurdle in translating promising gut microbiome research into effective therapeutic candidates is demonstrating the causative role of human microbiome in disease pathology. Although there are a growing number of microbiome-based candidates showing promising results in both pre-clinical and clinical settings, the approaches that are likely to have well-validated mechanisms of action are limited. The purpose of this theme will be to review the current thinking in approaching the human microbiome mechanistically to understand both the academic and industrial perspectives on this important topic.

9.00 **Microbiome, Host Genetics, and Metabolic Diseases**

- Addressing the effect of host genetics on human microbiome
- Evaluating the effect of specific microbial taxa and functional genes on metabolic diseases including obesity, T1D, and NAFLD
- Identifying the underlying mechanisms related to microbial functions



GwangPyo Ko
Professor
Seoul National University
CEO
KoBioLabs

9.30 **Impact of the Gut Microbiota in Korean Patients with GI Diseases**

- Impact of gut microbiota on the pathogenesis of IBD and colitis-associated cancer
- Microbiome and gastric carcinogenesis (chronic gastritis to intestinal metaplasia and gastric cancer)
- Review of recent research data



Changsoo Eun
Professor, Internal Medicine
Hanyang University College of Medicine

10.00 **Speed Networking Session**



11.00 **Morning Coffee & Refreshments Break**



12.00 **Faecalibacterium Prausnitzii Dynamics in the Human Gut Microbiome Underlying Atopic Dermatitis**

- Reviewing the nature of microbiome dysfunction underlying skin disease
- Studying gut microbiome from 132 subjects, including 90 patients with AD using 16S rRNA and metagenome sequence analysis
- Demonstrating how Faecalibacterium prausnitzii is strongly associated with AD through dysregulation of gut epithelial inflammation



Heenam Stanley Kim
Professor
Korea University, College of Health Sciences

Establishing Standardised Protocols for Microbiome Research

Session Purpose:

As the vast quantity of microbiome research continues to be translated into therapeutic, nutritional, biomarker and diagnostic applications, the development of standard operating procedures continues to be crucial to ensure the reproducibility and regulatory approval of these breakthrough products. The purpose of this theme will be to review the importance of creating standard protocols to allow for greater comparability and reproducibility between studies without dampening cutting-edge scientific innovation.

12.30 Introduction to the Japan Microbiome Consortium (JMBC): Establishing Standardized Protocols for Microbiome Research

- Exploring the mission and purpose of JMBC to help standardise microbiome research and accelerate industrialisation of human microbiome studies for medical and healthcare in Japan
- Understanding the importance of creating a unique Japanese database as a basis for new microbiome-based products and services of the future
- Exploring recent JMBC collaborations



Shingo Arioka
Research Manager
Shionogi & Japan Microbiome Consortium

13.00 Lunch Break & Networking



Sequencing, Bioinformatics & Big Data

Session Purpose:

The advent and accessibility of Next-Generation Sequencing (NGS) tools and bioinformatics analysis has provided the scientific community a novel way to analyse communities of microorganisms and understand the functional relationship between microbial dysbiosis and disease pathogenesis, without the need of cultivation. More recently, researchers have moved beyond 16S sequencing to integrate more complex analysis methods including shotgun metagenomics, metabolomics, metatranscriptomics etc. to move towards species and strain-level profiling. The purpose of this theme will be to review the current NGS methodologies used to analyse microbiome samples, how complex microbial datasets are being processed, and the technical challenges that need to be overcome to assist future microbiome studies.

14.30 Integrated Omics Approach for Understanding the Gut Ecosystem and Mental Disorders

- Proposing an integrated omics approach (combining metagenomics, metatranscriptomics and metabolomics) to uncover underlying mechanisms between gut microbiota and the immune system
- Demonstrating how butyrate production by the gut microbiota enhances differentiation of colonic regulatory T cells from naïve T cells
- Sharing the results of applying an integrated omics approach to animal models with MS



Hiroshi Ohno MD
Principal Investigator
RIKEN Center for Integrative Medical Sciences

15.00 Metagenomic and Metabolomic Analyses Reveal Dynamic Shifts in Gut Microbiota along the Adenoma-Carcinoma Sequence in Colorectal Cancer

- Performing feces metagenomic and metabolomic analyses on a large colorectal cancer cohort
- Presenting microbial species that were newly associated with multiple polypoid adenomas and intramucosal carcinomas, in addition to more advanced lesions
- Discussing the functional aspects of microbiota to present its potential role in tumorigenesis



Takuji Yamada
Associate Professor
Tokyo Institute of Technology

15.30 Afternoon Coffee & Refreshments Break



- 16.00 **Big Data and Multi-Omic Analysis of Microbiome Samples**
- Sulfidomics – Metabolomics using sulfur metabolites that indicate various redox states
 - Bayesian network analysis – Causal inference in microbiome
 - Microbiota management – Intervention method to Microbiota



Ken Kasahara
General Manager of
Microbiome Area
Chitose Bio

- 16.30 **Genomics and Bioinformatics in Microbiome Research**
- Using bioinformatics as a tool for next generation sequencing
 - Understanding global microbial geography using high throughput amplicon sequencing
 - The role of metagenomics and the human microbiome



Jon Sik Chun
Professor
Seoul National University

- 17.00 **Chairperson Closing Remarks**



Shingo Arioka
Research Manager
Shionogi & Japan Microbiome Consortium

- 17.10 **Close of Conference Day One and Reception Hosted by the Microbiome Movement**



"The Microbiome Movement – Drug Development Summit is one of best gatherings of researchers from industry, combined with the right mixture of cutting edge academic science."

David Cook, Former CSO, Seres Therapeutics, Previous Microbiome Movement Attendee

"This is a tremendous event, everyone who's important in this field, we're seeing them here and it's helping stimulate innovation in our own programs."

Ken Blount, CSO, Rebiotix, Previous Microbiome Movement Attendee

"It's one of the best conferences targeting the microbiome area. Over the last two years, the program has grown really nicely to address many of the different hurdles and opportunities that we're facing in the microbiome area."

Sara Malcus, CEO, Metabogen, Previous Microbiome Movement Attendee

APPLICATIONS IN THERAPEUTICS, NUTRITION & DIAGNOSTICS

7.20 **Registration & Morning Coffee**



8.20 **Chairperson Opening Remarks**



Shingo Arioka
Research Manager
Shionogi & Japan Microbiome Consortium

Microbiome-Based Therapeutic Discovery, Clinical Development and Manufacturing

Session Purpose:

Following from the ongoing interest in Fecal Microbiota Transplantations (FMTs), many researchers have begun to develop more characterised therapeutic candidates based on single-strain organisms, precise consortia of organisms, or metabolites produced by microbes. Currently, there has been a growing body of the use of microbiome-based therapeutics across a variety of disease phenotypes, including IBD, Diabetes, Cancer, Autism and many more. The purpose of this theme will be to review cutting-edge case studies from industry and academia on the use of microbiome-based therapeutics to reverse disease phenotypes driven by an unwanted dysbiosis in microbial composition.

8.30 **Translating the Human Microbiome into New Therapeutics and Dietary Supplements**

- Overview and update of platform technology and pipeline
- Developing microbiome-based "curebiotics" to treat a variety of disease areas, including autoimmune, metabolic, CNS and CKD
- Testing "carebiotics" as a source for microbiome-based functional health foods and dietary supplements



Taewook Nam
CTO
KoBioLabs

9.00 **Developing Microbiome into a Medicine**

- Exploring challenges in developing microbiome into a medicine
- An industrial overview
- Sharing experiences to develop the microbiome into immuno-oncologic medicine



Jisoo Pae
Founder & CEO
Genome and Company

9.30 **Bacillus Spore-Based Oral Biotherapeutics**

- Identifying and amplifying 'real effector molecules' from probiotic Bacillus strains already in use as food supplements or as drugs
- Developing orally available spore biotherapeutics
- Pre-clinical animal studies on inflammatory bowel disease, age-related muscular degeneration and other indications



Jae-Gu Pan
CTO
GenoFocus

10.00 **GI 310, a Novel Long-Acting IgE Trap-Fc Fusion Protein That Elicits Therapeutic Synergy in Combination with a Microbiome Agent for the Treatment of Food Allergy**



Yang Bo Gie
Chief Scientific Officer
GI Innovation

10.30 **Morning Coffee & Refreshments Break**



11.00 **The Asian Gut Microbiome: A New Therapeutics Discovery Opportunity**

- How is the Asian gut microbiome different than the Western gut microbiome?
- How does fecal microbiota transplant yield new drug discovery opportunities?
- How does the Asian gut microbes work in global populations?



Jonathan Krive
CEO
AsiaBiome

11.30

AI Approaches to Microbiome-based Drug Development in China

- Introducing the first AI-based microbiome drug development company in China
- Challenges of traditional drug discovery techniques for microbiome research
- Combining AI and bioinformatic analysis to create a unique drug development platform and improve the rate of drug success

**Yiming Yin**

VP, Research & Product
Development
XBiome

12.00

Clinical Trial for the Application of Probiotics for Intestinal Disorders**Ki-Tae Suk**

Associate Professor
**Hallym University Medical
Center**

12.30

Beneficial Microbes and Their Metabolites

- Search for new beneficial gut microbes
- Research on metabolites produced by gut microbes.
- Research on the industrialization of beneficial microorganisms as and their metabolites (Postbiotics) for use as drugs and foods

**Yasunori Yonejima**

Group Manager
Nitto Pharmaceuticals

13.00

Lunch Break & Networking**Microbiome-Based Biomarker Discovery: Patient Stratification Tools****Session Purpose:**

As molecular biomarkers continue to become an important component to diagnose disease and predicting response to treatment, the human microbiome has become a rich source for novel biomarker discovery across a broad range of disease phenotypes. The purpose of this theme will be to review current efforts in biomarker discovery and applications within the drug development and diagnostic industry.

12.30

Development of Endometrial Microbiome Testing for Reproductive Health

- Development of Endometrial Microbiome Testing
- 16S rRNA sequence analysis for low biomass
- How improve the endometrial environment when test result was not good

**Yoshiyuki Sakuraba**

CEO
Varinos

Role of the Human Microbiome in Diet, Nutrition and Health**Session Purpose:**

Closely followed by the research investigating the human microbiome's role in disease treatment, there are a growing number of clinical studies that demonstrate the role of dietary intake, microbial diversity & abundance and health management. Observations have shown that changes to the gut microbiota can occur within days of changing diets, which could therefore provide opportunity for product development. The purpose of this theme will be to review recent research and clinical studies to translate microbiome research into nutritional solutions of the future.

14.00

Early Life Nutrition and Its Relevance in the First 1000 Days: A Lifelong Microbial Journey Perspective

- Discussing how transgenerational microbial inheritance during pregnancy, birth and breastfeeding contribute to immune, metabolic and neurocognitive system development during early life
- Recognising that the first 1000 days as an important window to nurture child health and development
- Developing nutritional interventions that reduce disease risk associated with a compromised microbiome

**Christophe Lay**

Senior Scientist, Gut
Microbiome
Danone Nutricia Research

POLICY, REGULATION & INVESTMENT

Collaborations & Consortiums to Support Microbiome-Initiatives

Session Purpose:

Since the establishment of the Human Microbiome Project (HMP) and MetaHIT in 2008, there have been a growing number of global initiatives funded by government, academia and private organisations that look to accelerate translational microbiome research by exchanging methodologies, promoting standardisation and exchange ideas for the future applicability of this cutting-edge science. The purpose of this theme will be to highlight the successful efforts that are happening in the Asia-Pacific region as it relates to cooperating on microbiome-based research and the outcomes of these partnerships.

14.30 **Introduction and Overview of the Korea Society of Gut Microbiome (KSGM)**



Wang-Jun Lee MD
CEO & Chairman
MyongJi Hospital

15.30 **Afternoon Coffee & Refreshments Break**



16.00 **Introduction of the Asian Microbiome Project: Study on Correlation among Diet, Gut Microbiota and Overall Health of Asian People**



Lee Yuan Kun
Associate Professor
National University of
Singapore

Regulatory Frameworks for Microbiome-Based Products

Session Purpose:

As microbiome-based therapies constitute a novel paradigm in modern medicine, a robust regulatory framework that addresses key safety and CMC issues should be evaluated for safe implementation of these treatments to patients in need. Despite the rise in notoriety across the pharmaceutical industry, only a few regulatory agencies have provided clarity over the regulatory hurdles when developing a microbiome-based therapeutic. The purpose of this theme will be to outline how leading regulatory bodies in Asia and Internationally are currently reviewing microbiome candidates whilst highlighting successful IND applications for emerging and well established microbiome companies.

16.30 **Current Regulation of Microbiome-Based Therapeutics in Korea**



Suenie Park
Professor
Hallym University

17.00 **Chairperson Closing Remarks**



Shingo Arioka
Research Manager
Shionogi & Japan Microbiome
Consortium

17.10 **Close of Inaugural Microbiome Movement - Drug Development & Nutrition Summit**

SPONSORSHIP INFORMATION

Whether an organisation is committed to developing a microbiome-based therapeutic or nutritional product for consumers, there are universal challenges in product development that are consistent across different industry verticals. The *Microbiome Movement* partners with the leading service providers with capabilities in sequencing, bioinformatics analysis, manufacturing, formulation and other important areas of product development, to unite the value chain and further the progress of the microbiome field.

If you have relevant capabilities in the microbiome space and would like to align and elevate your brand with this market, partner with us and promote your expert capabilities through a bespoke commercial package.



Generate New Business Leads

In a fast growth market, secure valuable face time with key decision makers during our speed networking and pre-organised 1-2-1 meetings



Showcase the Capabilities of Your Solution

Demonstrate the uniqueness of your innovative product and services during the conference schedule of in our high-traffic networking area



Gain the Trust of Microbiome Product Developers

Position yourself amongst thought leaders on the conference agenda



Build Brand Awareness

Gain exposure to our expert audience through pre-event and onsite promotion



Exhibit Your Product or Service

With an exhibition booth in the main networking room, give potential customers hands-on insight into your capabilities and services



Expertise Partner

LuinaBio is Australia's most experienced biopharmaceutical CDMO's with 20 years' experience in our field. More specifically Luina carries out microbial aerobic and anaerobic fermentation, yeast fermentation, cell banking, vaccine production, process development, analytical services, stability studies, storage and distribution of investigative material for clinical studies.

www.luinabio.com.au



Expertise Partner

Quay Pharmaceuticals is a privately owned CDMO working from FDA and MHRA inspected facilities. We are licensed to formulate and manufacture the finished dosage forms for live biotherapeutics as well as small and large molecules. In the live biotherapeutic space we work with consortia and single strains for drug delivery in oral and topical formats.

Working as part of your team we rapidly and effectively bring products through development to First In Human studies to deliver success.

www.quaylivebio.com



Exhibition Partner

Biose Industrie is a Contract Development and Manufacturing Organization (CDMO), specialised in Live Biotherapeutic Products. Founded in 1951 by pharmacists and microbiologists, Biose Industrie has been manufacturing drug substance and drug products based on microorganisms for 60 years. Company, with 10 000m² of GMP facility, offers product development at laboratory and pilot scale specialised in microbiology for aerobic and anaerobic strains and is Drug GMP certified for the manufacturing of API, clinical batches and commercial products.

www.biose.com/en/cdmo

GET INVOLVED



Adam Haras-Gummer
Partnerships Director
Tel: +44 (0) 203 1418 727
Email: partner@microbiome-movement.com

REGISTRATION INFORMATION

TOP 3 REASONS TO ATTEND

1 **SAVE** valuable resources by learning how leading companies have optimised regulatory, clinical and manufacturing strategies

2 **GAIN** first-hand insights from the movers and shakers in the microbiome space

3 **FORM** lasting connections by engaging directly with colleagues from cutting-edge pharma and biotech companies actively developing microbiome-based solutions in an intimate environment

Industry Pricing	Register & Pay By Friday, June 28	Standard Pricing
2 Day Conference	\$1499 (save \$400)	\$1899

Academics/ Not-For-Profit	Register & Pay By Friday, June 28	Standard Pricing
2 Day Conference	\$799 (save \$200)	\$999

GROUP DISCOUNTS

10% discount – 2+ delegates

15% discount – 3+ delegates

20% discount – 4+ delegates

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Hilton Singapore

581 Orchard Road, Singapore
238883

**For further information or assistance,
please visit**

www3.hilton.com/en/hotels/singapore/hilton-singapore-SINHITW/index.html

TERMS AND CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Event Code: 13041

3 Ways To Book



www.microbiome-movement-asia.com



Tel: +1 617 455 4188



Email: register@hansonwade.com